Highlights d NLRP3 and P2Y2 interact and regulate susceptibility to HIV-1 infection d NLRP3 is an intrinsic inhibitory factor for HIV-1 that represses F-actin remodeling d HIV-1 Env binding to host receptors overcomes NLRP3 restriction by activating P2Y2 d P2Y2 activation leads to CBL-mediated NLRP3 degradation and favors viral entry
In Brief
Paoletti et al. identified a constitutive interaction between NLRP3 and P2Y2 that regulates HIV-1 entry into target cells. They revealed that NLRP3 represses viral entry by impairing F-actin reorganization. HIV-1 overcomes this host cellular resistance by inducing NLRP3 degradation through the activation of P2Y2-dependent signaling pathway.
INTRODUCTION
Although the stimulation of innate immunity with vaccine adjuvants has been extensively and efficiently harnessed for the control of major infectious diseases (such as diphtheria, tetanus, and poliomyelitis), the cellular and molecular mechanisms that orchestrate immune responses against pathogens remain largely elusive, especially with respect to the early steps of infection. Immune sensing of HIV-1 by pathogen recognition receptors (PPRs) and cytoplasmic DNA sensors may partially hinder (legend continued on next page) HIV-1 replication through the production of type-1 interferon (IFN) and the expression of restriction factors such as APOBEC3 cytidine desaminases, tetherin, and SAM domain and HD domain-containing protein 1 (SAMHD1) (Towers and Noursadeghi, 2014) . Despite the beneficial impact of the cell-autonomous innate immune system on HIV-1 replication, innate signals, converging on the DNA sensing interferon gamma inducible 16 protein (IFI16) inflammasome, can contribute to chronic immune activation and eventually to pyroptosis of uninfected CD4 + T cells, thereby enhancing disease progression (Doitsh et al., 2010 (Doitsh et al., , 2014 Monroe et al., 2014) . Given the ambiguous effects of innate immune signals on HIV-1 replication and disease progression, further exploration of the innate signaling molecular pathways that govern HIV-1 infection is needed.
Most studies on HIV-1 infection have explored innate mechanisms acting before or after viral entry. Little is known about innate signaling pathways elicited during viral entry. We previously reported that purinergic receptors, which are membraneanchored PPRs, promote the entry of HIV-1 into immune cells (Sé ror et al., 2011) . The binding of HIV-1 envelope (Env) to its cellular receptors (CD4, CXCR4, and/or CCR5) causes the release of adenosine triphosphate (ATP) from host cells through the opening of pannexin-1 hemichannels (PNX1). Once released, extracellular ATP stimulates purinergic receptors (including the purinergic receptor P2Y2) and facilitates the membrane fusion process through the activation of the proline-rich tyrosine kinase 2 (PYK2) that is required for viral entry (Sé ror et al., 2011) . The activation of the purinergic signaling pathway is indispensable for cell-free HIV-1 infection (Hazleton et al., 2012; Sé ror et al., 2011; Swartz et al., 2014) , as well as for cell-to-cell transmission of the virus between infected lymphocytes and target cells, which is the most efficient route of HIV-1 spreading (Sé ror et al., 2011; Swartz et al., 2014) . In this context, antagonists of purinergic receptors or pannexin-1 have emerged as a new class of HIV-1 microbicides (Sé ror et al., 2011) .
Other PPRs, the NOD-like receptors (NLRs), have also been involved in the establishment of viral infection. Initially described as crucial for sensing and initiating host defense in viral infection through the formation of inflammasome (Chen and Ichinohe, 2015) , NLRs (such as NLRX1) have recently been shown to be involved in the early innate response to simian immunodeficiency virus (SIV) infection and to contribute to viral replication by repressing the transcription of restriction factors (such as the interferon stimulated gene [ISG] 5, the myxovirus resistance 2 protein [MX2] , and the tripartite motif-containing protein [TRIM] 5; Barouch et al., 2016) . These results highlight the counterintuitive role of the inflammasome signaling, which indeed may facilitate (rather than repress) the early steps of HIV and SIV infections.
In this context and to further characterize cellular factors that may modulate P2Y2-dependent signaling during the early steps of HIV-1 infection, we studied the role of NLRs during viral infection. We identified the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) as a P2Y2-interacting protein. Considering that NLRP3 and P2Y2 are endogenously expressed in CD4 + T cells and cells from mononuclear phagocyte lineage (including monocytes and macrophages), we first studied the interaction between NLRP3 and P2Y2 during the cellular infection by HIV-1 and SIV. Then we characterized the biological consequences of the modulation of this interaction during the early steps of infection of macrophages, which are, together with T lymphocytes, the major target cells of HIV-1.
RESULTS

Enhancement of the Interaction between NLRP3 and P2Y2 during SIV and HIV Infection
Based on our previous work showing that the purinergic receptor P2Y2 contributes to the early steps of HIV-1 infection (Sé ror et al., 2011) , we searched for potential P2Y2-interacting NLR proteins, identifying NLRP3 as an interactor of P2Y2 ( Figure 1A ). The endogenous NLRP3 and P2Y2 proteins co-immunoprecipitated in human THP1 monocytes ( Figure 1A ), indicating that both proteins constitutively interact. Of note, this interaction increased after 3 h of infection of human THP1 monocytes with CXCR4-tropic (X4-tropic) HIV-1 NL4-3 (Figures 1A and S1A). We then studied the subcellular localization of NLRP3 during the early steps of HIV-1 infection obtained by coculturing of uninfected peripheral blood lymphocytes (PBLs) with X4-tropic HIV-1 NDK -infected PBLs. NLRP3 polarized toward the contact sites formed between HIV-1 NDK -infected and uninfected host cells (Figures 1B and 1C) . At these contact sites, NLRP3 colocalized with the glycoprotein gp120 (Figure 1B) and the purinergic receptor P2Y2 ( Figure 1C ). Thus, NLRP3 accumulated at the virological synapse that is formed between HIV-1 NDK -infected and uninfected PBLs ( Figure 1D ).
(E and F) PLA between P2Y2 and NLRP3 (E) and frequencies of positive signals (F) detected on interacting HIV-1-infected and uninfected lymphocytes are shown. The image is representative of three different donors. Data are presented as means ± SEM, and significance is *p % 0.05 (n = 29 virological synapses from three independent experiments), unpaired Mann-Whitney test. (G) Fluorescence intensities of NLRP3 in HIV-1-infected and uninfected lymphocytes obtained from confocal microscopy are shown a three-dimensional (3D) Z-projection. Representative experiment of three different donors is shown. (H and I) PLA between P2Y2 and NLRP3 (H) and frequencies of positive signals detected on ileum sections (I) obtained from SIV mac251 -infected and uninfected Macaca fascicularis are shown. Images are representative of four SIV mac251 -infected and three uninfected Macaca fascicularis. Data are presented as means ± SEM, and significance is ****p % 0.0001 (n = 3 uninfected, n = 4 uninfected), unpaired Mann-Whitney test. (J and K) PLA between P2Y2 and NLRP3 (J) and frequencies of positive signals detected on brain autopsies (K) from HIV-1-infected and uninfected individuals are shown. Images are representative of nine HIV-1-infected and two uninfected donors. Data are presented as means ± SEM, and significance is **p % 0.01 (n = 2 uninfected, n = 9 infected), unpaired Mann-Whitney test. (L and M) PLA between P2Y2 and NLRP3 (L) and frequencies of positive signals (M) detected during MDMs infection are shown. The image is representative of three different donors. Data are presented as means ± SEM, and significance is ****p % 0.0001 (n = 1,075 and 1,133 for uninfected and HIV-1 BaL infected MDMs, respectively), unpaired Mann-Whitney test. See also Figure S1 .
We determined the ability of NLRP3 to directly interact with P2Y2 by means of a proximity ligation assay (PLA). During the early steps of HIV-1 infection, the interaction between NLRP3 and P2Y2 mostly occurred at the contact sites between HIV-1 NDK -infected and uninfected T lymphocytes (Figures 1E and 1F) . These results suggest that the interaction between NLRP3 and P2Y2 may regulate the viral entry into target cells. We also studied the subcellular localization of NLRP3 after chronic infection of PBLs with X4-tropic HIV-1 NDK for 72 h (Figures 1G and S1B-S1D) or that of monocyte-derived macrophages (MDMs) with R5-tropic HIV-1 AD8 for 6 days (Figures S1E and S1F). While NLRP3 presented a diffuse cytosolic expression pattern in uninfected target cells, it aggregated in the cytoplasm and at the membrane of infected PBLs (Figures 1G and S1B-S1D) or MDMs (Figures S1E and S1F). Using PLA, we also evaluated the ability of NLRP3 to interact with P2Y2 during chronic infection and revealed that the interaction between NLRP3 and P2Y2 increased in 1M ). Altogether, these findings indicate that the interaction between NLRP3 and P2Y2 increased during acute and chronic steps of viral infection.
NLRP3 Inflammasome Activation Impairs HIV-1 Entry into Host Cells
To characterize the role of NLRP3-P2Y2 interaction and related signaling pathways during the early steps of HIV-1 infection, we first evaluated the possibility that the NLRP3 might affect viral replication through the formation of the inflammasome. Considering that sterile particulates such as monosodium urate (MSU) crystals are capable of activating the NLRP3 inflammasome (Shi et al., 2010) , we incubated MDMs with 100 mM MSU before infection with R5-tropic HIV-1 BaL and then analyzed their viral permissiveness. The activation of the NLRP3 inflammasome by MSU reduced the release of CAp24 capsid from human MDMs (Figure 2A ) and its intracellular detection ( Figure 2B ) after 3 days ( Figure 2A ) and 6 days ( Figures 2A and 2B ) of infection with R5-tropic HIV-1 BaL . This MSU-mediated inhibition of HIV-1 was more efficient than the one detected with lipopolysaccharide (LPS) (Figures 2A and 2B) . To further characterize the impact of NLRP3 inflammasome activation on the early steps of HIV-1 infection, we monitored the effects of MSU treatment on intracellular HIV-1 CAp24 capsid levels (after removal of membrane bound noninternalized virus with trypsin treatment) and on the early reverse transcripts that are detected after 6 and 24 h, respectively, of infection of human MDMs with R5-tropic HIV-1 AD8. These data revealed that NLRP3 inflammasome activation impaired the accumulation of intracellular HIV-1 CAp24 capsid ( Figure 2C ) and subsequently reduced the early reverse transcripts ( Figure 2E ) without affecting cell viability ( Figure S2A ) nor the membrane expression of the viral receptors CD4 ( Figure S2B ) and CXCR5 ( Figure S2C ). Accordingly, MSU did not impair the accumulation of intracellular HIV-1 CAp24 capsid in human MDMs that were infected by the HIV-1 NL4-3DENV variant (defective in viral envelope) pseudotyped with the vesicular stomatitis virus G protein (VSV-G) envelope, HIV-1 VSV-G ( Figure 2D ). Altogether, these results demonstrate that NLRP3 inflammasome activation inhibits HIV-1 entry into host cells.
NLRP3 Protein Inhibits HIV-1 Infection by Repressing the Cytoskeletal Remodeling Required for HIV-1 Entry
We determined the role of NLRP3 inflammasome protein during the early steps of HIV-1 infection through the knockdown of NLRP3 using specific short hairpin RNA (shRNA). We observed that the depletion of NLRP3 increased the release of CAp24 capsid from human MDMs ( Figure 3A Figures 3B and 3D ). After removing membranebound non-internalized HIV-1 particles by trypsinizing the cells, western blot detection of intracellular CAp24 capsid corroborated that the depletion of NLRP3 in MDMs increased cellular susceptibility to HIV-1 infection after 6 h of infection ( Figure 3F ). These data were confirmed by the depletion of NLRP3 in THP1 monocytes that were then infected with X4-tropic HIV-1 NL4-3 for 6 h ( Figures 3G and S3D ). To rule out the possibility that NLRP3 protein may also act at post-entry levels, we evaluated the effects of NLRP3 overexpression on viral yields after transfection of X4-tropic HIV-1 NL4-3 ( Figure S3E ) or R5-tropic HIV-1 AD8 ( Figure S3F ) DNA constructs that subsequently produce infectious virions. NLRP3 overexpression ( Figures S3E and S3F ) did not impact the amount and infectivity of X4-tropic HIV-1 NL4-3 ( Figures S3G and S3I ) and R5-tropic HIV-1 AD8 (Figures S3H and S3J ) produced 48 h post transfection. Consistently, the depletion of NLRP3 failed to increase infection of target cells by HIV-1 VSV-G ( Figures 3H and S3K ). These results imply that NLRP3 protein selectively inhibits receptor-mediated entry of HIV-1.
Emerging evidence has revealed important inflammasome-independent roles for ASC and CASP1 in controlling immune responses through the modulation of F-actin polymerization (Caution et al., 2015; Ippagunta et al., 2011) . In our previous report (Sé ror et al., 2011) , we demonstrated that following HIV-1 infection, P2Y2 enhances plasma membrane depolarization through the activating autophosphorylation of the prolinetyrosine kinase 2 (PYK2) on tyrosine residue 402 (PYK2Y402*) to favor the early fusion of the HIV-1 membrane and the target cell. Importantly, activated PYK2 is known to broadly modulate the F-actin rearrangement and polymerization to regulate immune cells migration, morphology or growth (Collins et al., 2010; Du et al., 2001; Okigaki et al., 2003; Ren et al., 2001; Wang et al., 2003) . F-actin remodeling is also required for HIV-1 membrane fusion with target cells and entry (Jimé nez- Baranda et al., 2007; Stolp and Fackler, 2011) . Considering that F-actin cytoskeletal remodeling and the associated PYK2 activation both contribute to HIV-1 early viral entry (Jimé nez- Baranda et al., 2007; Sé ror et al., 2011; Stolp and Fackler, 2011) , (G and H) Intracellular HIV-1 CAp24 analyzed by western blot in control and NLRP3-depleted THP1 cells infected for 6 h with X4-tropic HIV-1 NL4-3 (G) or HIV-1 NL4-3DEnv pseudotyped with VSV-G envelope (H). Representative western blots of three independent experiments are shown. (I) Confocal microscopy images of HIV-1 entry (detected with CAp24 and Vpr-GFP signals) in THP1 macrophages control and depleted for P2Y2 (shP2Y2) or for NLRP3 (shNLRP3-1 and 2) and infected for 6 h with R5-tropic HIV-1 AD8-Vpr-GFP in the presence or absence of latrunculin B (10 mM). Dashed lines indicate the cellular perimeters. The corresponding F-actin polymerization staining (with phalloidin) is shown in Figure S3L . Images are representative of three independent experiments. (J) Cell percentage of HIV-1 AD8-Vpr-GFP and F-actin polymerization positive cells determined by confocal microscopy as shown in (I) and in Figure S3L . Data obtained from three independent experiments are presented as means ± SEM (n = 300 cells). Significance levels are *p % 0.05 and ****p % 0.0001, ANOVA test. (K) NLRP3, PYK2Y402*, PYK2, and intracellular CAp24 analyzed by western blot of control and NLRP3-depleted THP1 macrophages pretreated 18 h with AR-C118925XX (100 mM) and infected with R5-tropic HIV-1 AD8 for 6 h treated in the presence of the drug. Western blots are representative of three independent experiments.
we hypothesized that NLRP3 may antagonize the effects of activated P2Y2 and PYK2 on F-actin remodeling upon HIV-1 infection, thereby inhibiting HIV-1 entry. Confocal microscopy analysis revealed that NLRP3 depletion increased the entry of GFP-fused viral protein (Vpr) containing viral particles (HIV-1 AD8-Vpr-GFP ) (McDonald et al., 2002) into PMA-THP1 macrophages, as revealed by the intracellular detection of HIV-1 AD8-Vpr-GFP and CAp24 ( Figures 3I and 3J ). The enhanced viral entry into NLRP3-depleted cells was associated with an increase of F-actin cytoskeletal polymerization ( Figures 3J and S3L ). Moreover, inhibition of F-actin polymerization by latrunculin B abrogated the stimulation of HIV-1 infection by NLRP3 depletion (Figures 3I, 3J , and S3L). Consistently, the selective P2Y2 antagonist AR-C118925XX abrogated the NLRP3 depletion-driven signaling pathway (as revealed by the decreased of PYK2402* and intracellular CAp24 level [ Figure 3K ]) in NLRP3-depleted THP1 macrophages that were infected with R5-tropic HIV-1 AD8 for 6 h. Altogether, these results demonstrate that, independently from its contribution to the inflammasome, NLRP3 protein acts as an endogenous repressor of F-actin cytoskeletal polymerization that facilitates the P2Y2-dependent entry of HIV-1 into target cells.
NLRP3 Is Degraded during the Early Steps of HIV-1 Infection
To determine how HIV-1 may overcome the NLRP3-mediated inhibition of its entry into host cells, we simultaneously measured NLRP3 and P2Y2 expressions during infection. (legend continued on next page) Despite the fact that P2Y2 protein levels increased, NLRP3 protein levels rapidly decreased after cell-free infection of MDMs with R5-tropic HIV-1 BaL (Figure 4A ), THP1 monocytes ( Figures  4B, S4A, S4B , and S4E-S4H) and CEM-SS T cells ( Figures  S4C, S4D , and S4I-S4L) with X4-tropic HIV-1 NL4-3 ( Figures  4B, S4A, S4C, S4E, S4F , S4I, and S4J) or R5-tropic HIV-1 AD8 (Figures S4B, S4D, S4G, S4H, S4K, and S4L) , and PBLs with X4-tropic HIV-1 NDK (Figure 4C ). However, NLRP3 mRNA expressions were not altered after infection of THP1 monocytes (Figures S4M and S4N ) and CEM-SS T cells ( Figures S4O and  S4P ) with X4-tropic HIV-1 NL4-3 ( Figures S4M and S4O ) and R5-tropic HIV-1 AD8 (Figures S4N and S4P) . The ubiquitin isopeptidase inhibitor G5 that was previously described as an inducer of NLRP3 degradation (Py et al., 2013) decreased the protein levels of NLRP3 ( Figure 4D ), thus suggesting that the reduction of NLRP3 protein expression induced by HIV-1 infection must occur through post-transcriptional mechanisms. This process is associated with the enhancement of P2Y2 expression and HIV-1 permissiveness of THP1 monocytes (as indicated by the increased intracellular accumulation of HIV-1 capsid CAp24) ( Figure 4D ), in line with the hypothesis that NLRP3 and P2Y2 control HIV-1 entry into target cells. Consistently, we observed that the depletion or the overexpression of NLRP3 ( Figures S5A-S5C ) enhanced or reduced, respectively, HIV-1 Env-elicited fusion ( Figures 4E-4G) , the intracellular accumulation of HIV-1 CAp24 capsid ( Figures S5D-S5F) , and the susceptibility to HIV-1 infection ( Figure 4E-4G) , without affecting the expression of the HIV-1 receptor CD4 and that of its co-receptor CXCR4 (Figures S5G-S5I ). Consistent with our previous report (Sé ror et al., 2011) , we confirmed that the P2Y2 inhibitor AR-C118925XX ( Figure S5J ) and shRNA-mediated P2Y2 depletion ( Figure S5K ) impaired the entry of R5-tropic HIV-1 AD8 into MDMs ( Figure S5J ) or of X4-tropic HIV-1 NL4-3 into THP1 monocytes ( Figure S5K ). This effect is associated with the increased expression of NLRP3 in target cells ( Figure S5K ). We also evaluated the impact of the selective activation of P2Y2 by uridine triphosphate (UTP) in THP1 cells infected with X4-tropic HIV-1 NL4-3 for 6 h on the NLRP3 and P2Y2 interaction and on the levels of NLRP3. P2Y2 activation led to a significant enhancement of the NLRP3-P2Y2 interaction associated with the degradation of NLRP3 and an increase of HIV-1 entry into cells (Figures 4H,   S5L , and S5M). Altogether, these data indicate that the activation of P2Y2 occurring shortly after HIV-1 infection increases the susceptibility of cells to viral entry by inducing NLRP3 protein degradation.
HIV-1 Envelope Overcomes NLRP3 Inhibition through the Activation of the E3 Ubiquitin Ligase CBL To define the molecular mechanisms accounting for the degradation of NLRP3 during the early steps of infection, HEK293T cells were transfected with full-length NLRP3, with GFP-tagged full-length P2Y2, or with both constructs. Co-expression of GFP-P2Y2 with NLRP3 reduced the expression of NLRP3 protein, while co-expression of NLRP3 failed to reduce the expression of GFP-P2Y2 ( Figure 5A ). The downregulation of NLRP3 by P2Y2 was increased by the ubiquitin isopeptidase inhibitor G5 and fully blocked by the proteasome inhibitor MG132 ( Figures  5A and S6A ), thus demonstrating that upon P2Y2 activation, NLRP3 is ubiquitinylated and degraded by the proteasome. Considering that the ubiquitinylation and subsequent degradation of NLRP3 can be initiated by ubiquitin ligases such as E3 ubiquitin ligase CBL through its SRC kinase-dependent phosphorylation (on tyrosine 731, CBLY731*) (Kankkunen et al., 2014; Py et al., 2013) , we checked whether the kinase SRC that was previously described as a downstream target of P2Y2-dependent signaling pathway (Liu et al., 2004 ) may interact with NLRP3 and control its degradation through the activation of CBL. Indeed, the kinase SRC co-immunoprecipitated with NLRP3 when NLRP3 was ubiquitinylated and degraded ( Figure 5B ). Moreover, pharmacological inhibition of SRC with PP1 or PP2 impaired the interaction between NLRP3 and P2Y2 ( Figure S6B ) and favored NLRP3 accumulation in THP1 cells ( Figure S6B ). Moreover, in HEK293T cells, transfection of full-length SRC together with full-length NLRP3 and GFP-tagged full-length P2Y2 led to an increased expression and phosphorylation of CBL on tyrosine 731 (CBLY731*) as well as to NLRP3 degradation ( Figure 5C ). Since the SRC kinase is a candidate for proteasomal degradation through a CBLdependent process (Sandilands et al., 2012) , we next investigated the role of CBL in P2Y2-induced degradation of NLRP3. Indeed, CBL depletion abolished the negative effect of GFP-P2Y2 on the overall abundance of the NLRP3 protein ( Figure 5D ). Altogether, these results suggest that P2Y2 controls NLRP3 (E-G) PHA/IL-2-stimulated human lymphocytes (E), MDMs (F), and THP1 cells (G) were infected, respectively, for 3, 3, or 6 h with X4-tropic HIV-1 NDK (E), R5-tropic HIV-1 BaL (F), or X4-tropic HIV-1 NL4-3 (G) and analyzed by western blot for CBLY731* and CBL relative expressions. Representative western blots of three independent experiments are shown. Relative expressions data from n = 3 independent experiments are presented as means ± SEM. Significances are **p % 0.01, ***p % 0.001, and ****p % 0.0001, unpaired t test. (H and I) Confocal microscopy image (H) of CBL and gp120 polarization during HIV-1-infected and uninfected lymphocyte interactions. Frequencies of CBL polarization during HIV-1-infected and uninfected lymphocyte interactions are shown (I). Images are representative of three different donors. Data are presented as means ± SEM, and significance is ****p % 0.0001 (n = 3 independent donors), unpaired t test. (J) Intracellular CAp24 analyzed by western blot and its relative expression in control and CBL-depleted MDMs were infected for 6 h with HIV-1 AD8 . Representative western blots of three independent experiments are shown. Relative expression data from three independent experiments are presented as means ± SEM. Significance is ****p % 0.0001 (n = 3 independent donors), unpaired t test. (K and L) Intracellular CAp24 analyzed by western blot of CBL-depleted CD4 + CXCR4 + cells were infected with HIV-1 NL4-3 (K) or HIV-1 VSV-G (L) for 6 h. Representative western blots of three independent experiments are shown. Relative expression from n = 3 independent experiments are presented as means ± SEM. Significance is ****p % 0.0001, unpaired t test. (M) Expressions of CBLY731*, CBL, P2Y2, and intracellular CAp24 analyzed by western blot in control and P2Y2-depleted THP1 macrophages infected for 6 h with R5-tropic HIV-1 AD8 . Representative western blots of three independent experiments are shown. Relative expression of CBLY731* from n = 3 independent experiments are presented as means ± SEM. Significance is ****p % 0.0001, unpaired t test.
degradation through a pathway involving the CBL ubiquitin ligase.
Next, we studied the role of the E3 ubiquitin ligase CBL during the early steps of HIV-1 infection. We detected increased CBL expression during cell-free infection of PBLs ( Figure 5E ), MDMs ( Figure 5F ), and THP1 monocytes ( Figure 5G ). This process was associated with the activating phosphorylation of CBL on tyrosine 731 (CBLY731*) 3 h post-infection of macrophages with R5-tropic HIV-1 BaL (Figure 5F ). We also studied the subcellular localization of CBL after co-culture of X4-tropic HIV-1 NDK -infected and uninfected PBLs. CBL polarized toward the contact sites formed between HIV-1-infected and uninfected cells ( Figures 5H and 5I) , where it colocalized with the HIV-1 glycoprotein gp120 ( Figure 5H ). Immunofluorescence microscopy confirmed that the NLRP3/P2Y2 interaction occurs at sites of viral entry during virological synapse formation between HIV-1 NDK -infected and uninfected lymphoblasts ( Figures 1C-1E ), as well as upon cell-free infection of PBLs (Figures S1I and S1J) or MDMs (Figures 1L and 1M ). We finally determined whether the E3 ubiquitin ligase CBL that is involved in the regulation of NLRP3 expression ( Figure 5D ) and relocalizes to the HIV-1-induced virological synapse ( Figures 5H and 5I) might control viral entry. MDMs ( Figure 5J ) or CD4 + CXCR4 + HeLa cells ( Figure 5K ) were depleted of CBL and infected for 6 h with R5-HIV-1 AD8 or X4-tropic HIV-1 NL4-3 , respectively. The depletion of CBL inhibited HIV-1 entry into target cells (as indicated by reduced intracellular HIV-1 CAp24 capsid; Figures 5J and 5K) . Moreover, CBL depletion failed to reduce cell permissiveness to HIV-1 VSV-G ( Figure 5L) , again suggesting that the E3 ubiquitin ligase CBL controls P2Y2-dependent viral entry mediated by the viral envelope. To demonstrate the functional link between CBL function and P2Y2 activation during HIV-1 infection, P2Y2-depleted THP1 macrophages and control cells were infected with R5-tropic HIV-1 AD8 for 6 h. P2Y2 depletion impaired the activating phosphorylation of CBL on tyrosine 731 (CBLY731*) ( Figure 5M ). This effect was associated with increased expression of NLRP3 and reduced entry of HIV-1 into target cells ( Figure 5M ). Altogether these results suggest that the binding between HIV-1 Env and its host cell receptors (CD4 and chemokine co-receptors) induces the recruitment of the E3 ubiquitin ligase CBL to viral entry sites for modulating the functional interaction between NLRP3 and P2Y2 interaction, thus facilitating viral entry.
DISCUSSION
Deciphering the complex network of innate signaling pathways is crucial for understanding the function of immune cells (such as monocytes, macrophages, and dendritic cells) that might constitute prime targets for prophylactic or therapeutic intervention in various human pathologies (such as autoinflammatory, autoimmune, infectious, and neoplastic diseases). Innate immune signals reportedly play contrasting roles during the acute and chronic phases of HIV-1 infection (Doitsh et al., 2014) . Recently, rapid inflammasome activation was reported following SIV infection of Rhesus monkeys (Barouch et al., 2016) . During early SIV pathogenesis, NLRX1-mediated inhibition of inflammasome activation represses the transcription of antiviral restriction factors (such as ISG5, MX2, APOBEC3, and TRIM5) and facilitates early viral replication (Barouch et al., 2016) . Here, we report that the expression of NLRP3 proteins is modulated through post-translational modifications during the early steps of HIV-1 infection and controls target cell susceptibility. We observed that following the binding of HIV-1 envelope to its host receptors (CD4, CXCR4, and/or CCR5), the interaction between NLRP3 and P2Y2 rapidly increased after HIV-1 infection, leading to the degradation of NLRP3 by The binding of HIV-1 envelope to its receptor (CD4) and co-receptors (CXCR4 or CCR5) leads to rapid ATP release from host cells through pannexin-1 (PNX1) and activates P2Y2. Once activated, P2Y2 enhances its interaction with NLRP3 and activates and favors the recruitment of SRC and CBL to NLRP3 (B), leading to NLRP3 ubiquitinylation and degradation. NLRP3 degradation leads to PYK2 phosphorylation (PYK2Y402*) and subsequent F-actin polymerization, which is required for the entry of HIV-1 into host cells (C). the E3 ubiquitin ligase CBL, thus favoring P2Y2-dependent viral entry into target cells through PYK2-dependent F-actin polymerization. Indeed, the interaction between HIV-1 Env and its co-receptors enhances the interaction between NLRP3 and P2Y2 and subsequently induces the degradation of NLRP3 by CBL, favoring the activation (phosphorylation) of PYK2 (PYK2Y402*) and subsequent cytoskeletal rearrangement (through F-actin polymerization) that facilitates HIV-1 early membrane fusion with target cells (Jimé nez- Baranda et al., 2007; Stolp and Fackler, 2011; Vorster et al., 2011) and hence viral entry ( Figure 6 ).
Our results are in agreement with published works supporting the notion that polymorphisms affecting the NLRP3 gene could influence the susceptibility to HIV-1 infection (Pontillo et al., 2010 (Pontillo et al., , 2012 and coinfection with Mycobacterium tuberculosis (Pontillo et al., 2013) . Altogether, our results suggest that HIV-1 (through its envelope protein) hijacks the functional crosstalk between NLRP3 and P2Y2 to optimize its viral life cycle.
The observation that the depletion of NLRP3 enhanced the infectivity of host cells by HIV-1 suggests that NLRP3 proteins function as intrinsic inhibitory factors for HIV-1 infection. In sharp contrast to the vast majority of identified inhibitory factors that impair viral infection at post-entry steps (Harris et al., 2012) , NLRP3 proteins limit HIV-1 infection by interfering with viral entry, suggesting that the NLRP3-P2Y2 interaction could be targeted for the prevention and treatment of HIV-1 infection. NLRP3 inflammasome activators (such as LPS or MSU crystals) reduce the susceptibility of HIV-1 target cells through the modulation of P2Y2-dependent F-actin remodeling. Thus, strategies designed to alter the functional interaction between NLRP3 and P2Y2 could effectively block HIV-1 infection. Nevertheless, the identification of the inflammasome inhibitor NLRX1 as transcriptional repressor of restriction factors that impair viral replication (Barouch et al., 2016) underlines the complexity of signaling pathways elicited by NLRP3 family members during the early steps of HIV-1 infection. Further molecular investigations are required to fully understand the role of NLRP3 family members during these viral steps. Future investigations must address the impact of the functional NLRP3-P2Y2 interaction on cellular regulators that are known to affect cortical F-actin rearrangement and to HIV-1 infection such as LIM domain kinase 1 (Vorster et al., 2011 ), moesin (Barrero-Villar et al., 2009 ), filamin-A (Jimé nez- Baranda et al., 2007) , and cofilin (Yoder et al., 2008) .
There may be differences between the acute and the prolonged effects of HIV-1 on the aforementioned regulatory system. Indeed, immunoreactive NLRP3 was detected at higher levels in lymph nodes (Figures 7A and 7B ) and in the frontal cortex ( Figures 7C and 7D ) from untreated HIV-1 carriers, as compared with uninfected specimens. Similar results were obtained when comparing control tissues from the non-human primate Macaca fascicularis with lymph nodes (Figures 7E and 7F) or intestinal tissues (colon in Figures 7G and 7H ; ileum in Figures 7I and 7J ) from macaques infected with SIV mac251 .
NLRP3 expression was preferentially observed in CD163 + macrophages (Figures 7G, 7I , and 7J) that are known to express P2Y2 (Elliott et al., 2009) . After 21 days of infection of THP1 monocytes and CEM-SS T cells with X4-and R5-tropic viruses, respectively, NLRP3 protein expression was increased ( Figures  S7A-S7F, S7I, and S7J) , although no modification of NLRP3 mRNA levels was detectable ( Figures S7M-S7P ). P2Y2 protein expression did not change in CEM-SS T cells but increased after 21 days of infection of THP1 monocytes (Figures S7G,  S7H, S7K, and S7L) . Altogether, these results suggest that the molecular mechanisms involved in the enhanced interaction between NLRP3 and P2Y2 that is detected during chronic infection with HIV-1 may be distinct from those detected in the early steps of HIV-1 infection. The increased NLRP3 expression during chronic HIV-1 infection is consistent with recent findings showing that HIV-1 activates NLRP3 inflammasome through Tat and Vpr proteins in lymphocytes, microglial cells, and macrophages (Bandera et al., 2018; Chivero et al., 2017; Haque et al., 2016; Mamik et al., 2017) . Thus, NLRP3 may play a dual opposite role during early steps of infection by inhibiting viral entry and at the later post-entry steps by contributing to neuroinflammation and immune activation associated with HIV-1 infection.
The blockade of immune checkpoints in lymphocytes has recently emerged as a new and promising approach for treating both chronic viral infection and cancer. Here, we identified a functional interaction that acts on myeloid cells and that could be exploited for the development of HIV vaccines or therapeutic combinations to cure HIV infection (Barouch et al., 2016) and potentially other viral infections (such as hepatitis B and C). In addition, it appears likely that the NLRP3-P2Y2 interaction could be manipulated for the treatment of HIV-1associated brain disease, which is also associated with strong activation of the NLRP3 inflammasome (Walsh et al., 2014) . Future studies should explore the possibility of modulating the NLRP3-P2Y2 functional interaction with the aim of treating human diseases that are triggered by excessive activation of the NLRP3 inflammasome, such as cryopyrin-associated periodic syndromes (Agostini et al., 2004) , rheumatoid arthritis (Vande Walle et al., 2014) , obesity (Vandanmagsar et al., 2011) , or Alzheimer's disease (Halle et al., 2008) .
Thus, our data demonstrate a constitutive interaction between NLRP3 and P2Y2 that could be targeted to reduce viral propagation and improve the immune response against HIV infection.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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This work was supported by funds from Agence Nationale de la Recherche (ANR-10-IBHU-0001, ANR-10-LABX33, and ANR-11-IDEX-003-01), Electricité de France, Fondation Gustave Roussy, Institut National du Cancer (INCA 9414) . T cells were prepared from the monocyte depleted cell fraction of PBMCs. Peripheral blood lymphocytes (PBLs) were activated for 48 hours in fresh medium supplemented with 2.5 mg/ml PHA (Sigma-Aldrich) and 1 mg/ml rhIL-2 (PeproTech). PBLs were then washed and cultured in growth medium containing 1 mg/mL rhIL-2 for 24 hours before HIV-1 infections.
Non-Human primates
Adult cynomolgus macaques (Macaca fascicularis) (four males and three females) were imported from Mauritius and housed in the facilities of the ''Commissariat à l'Energie Atomique et aux Energies Alternatives'' (CEA, Fontenay-aux-Roses, France). The protocols employed were approved by the ethical committee of the CEA ''Comité d'Ethique en Experimentation Animale'' registered in the French Research Ministry under number 44. Samples from lymph nodes, ileum and colon tissues were obtained from Macaca fascicularis that have been infected at the age of 5 years old by intrarectal inoculation with a single dose of 50 50% animal infectious doses (AID 50 ) of SIV mac251 . Tissues were collected during animal necropsy (for SIV mac251 -infected animals, on days 701 to 738 after SIV infection) after sedation of the animals (ketamine chlorhydrate 10 mg/kg) followed by euthanasia (injection of sodium pentobarbital 180 mg/kg). Non-human primates (NHP, which includes M. fascicularis) were used at the CEA in accordance with French national regulation and under national veterinary inspectors (CEA Permit Number A 92-032-02). The CEA is in compliance with Standards for Human Care and Use of Laboratory of the Office for Laboratory Animal Welfare (OLAW, USA) under OLAW Assurance number #A5826-01. The use of NHP at CEA is also in accordance with recommendation of the European Directive (2010/63, recommendation N 9). Animals were housed in adjoining individual cages allowing social interactions, under controlled conditions of humidity, temperature and light (12-hour light/12-hour dark cycles). Water was available ad libitum. Animals were monitored and fed 1-2 times daily with commercial monkey chow and fruits by trained personnel. Macaques were provided with environmental enrichment including toys, novel foodstuffs and music under the supervision of the CEA Animal Welfare Body. The animals were used under the supervision of the veterinarians in charge of the animal facility. Experimental procedures were conducted after animal sedation with ketamine chlorydrate (Rhone-Merieux, Lyon, France, 10 mg/kg) as previously described (Dioszeghy et al., 2006) .
Human autopsies
Human autopsies from axillary lymph nodes and frontal cortex were obtained in accordance with the Italian and EU legislations, after approval by the Institutional Review Board of the Lazzaro Spallanzani National Institute for Infectious Disease (Ethics Committee approval number 40/2006). Axillary lymph nodes and post-mortem frontal cortex sections were obtained from healthy (6 and 5, respectively) and HIV-1-infected individuals (6 and 11, respectively) (all men, mean age 36 years, the median values of HIV-1 viral load was 4.5 ± 0.6 log 10 cp/ml and < 500 CD4 T cells/ml). Frontal cortex sections were obtained from patients with HIV-1-associated dementia.
METHODS DETAILS
Plasmids and transfections NLRP3 coding sequence in the pUNO vector was purchased from Invivogen. The Flag-tagged NLRP3 full-length coding sequence was inserted in the 3xFlag-pcDNA3 and are a kind of gift from Gabriel Nunez (He et al., 2014) . The sequence coding for P2Y2 (in the pEFGP-N1 vector) is gift from Laura Erb . Transient transfections of HeLa CD4 + CXCR4 + cells (2.4x10 5 ) or HEK293T (3x10 5 ) cells with mammalian expression vectors (1-5 mg) were performed using Fugene transfection reagent (Promega), following the manufacturer's instructions. Western blot, immunoprecipitation analyses and experiences of HIV-1 infection or cell fusion were performed 24 hours after transfection. The transfection of pHIV-1 AD8 and pHIV-1 NL4-3 in HEK293T were performed 48 hours after transfection of pFlag-Luciferase or p3xFlag-NLRP3.
siRNA-and shRNA-mediated knockdowns
For HeLa CD4 + CXCR4 + knockdown the small interfering RNAs (siRNAs) used against NLRP3 were purchased from Sigma and had the following sequences: NLRP3, siRNA-1, 5 0 -GGAUCAAACUACUCUGUGA-3 0 ; siRNA-2, 5 0 -UGCAAGAUCUCUCAGCAAA-3 0 and the corresponding control siRNA, 5 0 -UUCAAUAAAUUCUUGAGGU-3 0 . The siRNAs against CBL used for primary MDMs and
